YouTube video by TexasTibbers

DBV Technologies (Nasdaq: DBVT), a late-stage biopharmaceutical company, will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, in Miami, FL.CEO Daniel Tassé will not attend the previously scheduled fireside chat due to travel disruption.

DBV Technologies (Nasdaq: DBVT) reported full year 2025 results and a business update focused on advancing VIASKIN® Peanut Patch clinical programs for ages 1–7 and preparing for BLA submissions.Key facts: positive Phase 3 VITESSE topline, 2025 PIPE and ATM financings, $194.2M cash at 12/31/2025 plus $94M received January 2026, and cash runway into Q2 2027.

Using AI to find stock market opportunities.

Using AI to find stock market opportunities.

Profit on the stock market by investing in biotech stocks

YouTube video by WFAA

DBV Technologies (Nasdaq: DBVT) has agreed to sell approximately $50 million of American Depositary Shares (ADSs) under its At-The-Market (ATM) program on Nasdaq to RA Capital Management, through Citizens JMP Securities as sales agent. Each ADS represents five new ordinary shares.The company will issue 18,288,220 new ordinary shares (3,657,644 ADSs) at $13.67 per ADS, equivalent to €2.3824 per ordinary share, a 0.15% discount to the last Euronext Paris closing price of €2.39. Settlement and delivery are expected on August 3, 2026.The new shares will represent 6.18% of existing Euronext Paris-listed shares and imply approximately 5.82% dilution for current shareholders. Post‑transaction, total shares increase from 296,087,162 to 314,375,382, with RA Capital holding 18,288,220 shares (5.82% of capital).

DBV Technologies (Nasdaq: DBVT, Euronext: DBV) has filed an automatically effective shelf registration statement on Form S-3ASR with the SEC, including a base prospectus and a sales agreement prospectus supplement, to refresh its existing at-the-market offering program for up to $150 million of American Depositary Shares (ADSs).The ATM program, conducted under a September 5, 2025 sales agreement with Citizens JMP Securities acting as sales agent, keeps total capacity at $150 million by carrying forward previously registered but unsold ADSs and adding newly registered capacity. Each ADS represents five ordinary shares, and issuances are subject to French regulatory limits, including a Prospective Regulation exemption for offerings to qualified investors representing less than 30% of securities already admitted over 12 months. DBV intends to use any net proceeds mainly for manufacturing expansion, BLA activities in ages 1–3 and 4–7, potential launch preparation of Viaskin Peanut in ages 4–7 if approved, product development, and general corporate purposes.

Covering the semester ended June 30, 2026, the filing is available in French to consult or download via the company and AMF websites.

DBV Technologies (Nasdaq: DBVT) reported second quarter and half-year 2026 results, highlighting continued regulatory progress for the VIASKIN® Peanut Patch in children aged 4–7 years. The company is engaged in detailed, ongoing interactions with the FDA and now anticipates submitting its BLA in the third quarter of 2026, with no additional data requested to date.DBV closed enrollment in the COMFORT Toddlers safety study, initiated the THRIVE study in infants, and remains funded into the third quarter of 2027, supported by $174.9 million in cash and cash equivalents at June 30, 2026. For the first half of 2026, operating income was $1.6 million, operating expenses $100.1 million, and net loss $98.0 million, or $(0.23) per share, compared with a $(0.58) loss per share a year earlier. Net cash used in operating and investing activities rose to $102.6 million, reflecting increased clinical, manufacturing, and commercial readiness investments.